IP Litigation partner Keith Zullow and senior associate Jenny Zhang examine upcoming U.S. pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma companies looking to access the U.S. market in European Pharmaceutical Review.
Related Content
- Securities SnapshotFebruary 21, 2023
Court Dismisses Class Action Against Coinbase Alleging Sale of Unregistered Securities
- In the PressJanuary 27, 2023
Cannabis Marketing Proposed Regulations in New York & Neighboring States (Bloomberg Law)
- AlertJuly 28, 2022
Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System
- Weekly RoundUpJune 30, 2022
SEC Announces Spring 2022 Regulatory Agenda
- Weekly RoundUpJune 9, 2022
SEC Proposes ESG Disclosure Rules and Changes to the Names Rule
- Weekly RoundUpMay 5, 2022
OCC Acting Comptroller Issues Statement on Stablecoin Standards
- Weekly RoundUpMarch 24, 2022
FINRA Reminds Firms About CCO Supervisory Liability
- Weekly RoundUpMarch 10, 2022
FinCEN Warns Against Evasion of Russian Sanctions
- Awards and RankingsMarch 17, 2023
Benchmark Litigation US Awards Name Goodwin Massachusetts Firm of the Year
- In the PressMarch 16, 2023
California Supreme Court Review: February 2023 (Daily Journal)
- Press ReleaseMarch 14, 2023
Momentive Global Enters into Definitive Agreement to Be Acquired by Symphony Technology Group for $1.5 Billion
- Press ReleaseMarch 13, 2023
Qualtrics To Become a Private Company Through $12.5 Billion Acquisition by Silver Lake and CPP Investments
- In the PressMarch 10, 2023
Mini-TCPA Laws You Should Know and That May Be Coming Soon in 2023 (Westlaw Today)
- In the PressMarch 3, 2023
Goodwin Hires Disputes Pro (Law360)
- In the PressFebruary 22, 2023
CFPB Advisory Opinion Details RESPA Implications for Mortgage Comparison Websites (Westlaw Today)
- Press ReleaseFebruary 21, 2023
Goodwin Year-In-Review Confirms 2022 Was a Regulatory Harbinger of What is in Store for The Consumer Finance Industry In 2023